A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT. - Mushtaq MU; DiPersio JF; Azzi J; Cooper BW; Koehne G; Koura D; Maakaron J; Magenau J; McClune B; Rimando JC; Shah NN; Suh HC; et al. (Blood, 2026)